NewsBenzingaMonte Rosa Reports Data From GFORCE-1, Phase 1 Study Evaluating MRT-8102, NEK7-Directed MGD Being Developed For Treatment Of Inflammatory Conditions Driven By NEK7/NLRP3 Pathway Monte Rosa Reports Data From GFORCE-1, Phase 1 Study Evaluating MRT-8102, NEK7-Directed MGD Being Developed For Treatment Of Inflammatory Conditions Driven By NEK7/NLRP3 Pathway Benzinga 2026.10.01 11:15 (GMT+0) Open on Benzinga Other news Elon Musk Says Optimus, Cybercab Will Be ‘the Vast Majority’ of Tesla’s Value iPhone Duo Preorders, AAPL Crosses $5 Trillion and More: This Week in Appleverse Wall Street Week Ahead Nscale's IPO plans hit another snag: Microsoft exits data center project Inflation Shakes Fed Outlook Crude Oil Surges, Sanders Targets Oil Companies and More: This Week in Economy AI Investment Impact Understated In U.S. 'It' Market: Texas Reveals
Inflation Shakes Fed Outlook Crude Oil Surges, Sanders Targets Oil Companies and More: This Week in Economy
